Simplicity Solutions LLC Sells 128 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Simplicity Solutions LLC trimmed its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,700 shares of the company’s stock after selling 128 shares during the period. Simplicity Solutions LLC’s holdings in BeiGene were worth $667,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Baillie Gifford & Co. grew its holdings in BeiGene by 17.9% during the third quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company’s stock valued at $696,384,000 after purchasing an additional 588,294 shares during the period. BlackRock Inc. boosted its holdings in shares of BeiGene by 3.8% in the first quarter. BlackRock Inc. now owns 2,699,444 shares of the company’s stock worth $509,114,000 after acquiring an additional 98,316 shares during the period. FMR LLC boosted its holdings in shares of BeiGene by 3.0% in the third quarter. FMR LLC now owns 2,352,730 shares of the company’s stock worth $423,186,000 after acquiring an additional 69,297 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of BeiGene by 68.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 775,857 shares of the company’s stock worth $167,222,000 after acquiring an additional 314,764 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of BeiGene by 10.9% in the second quarter. Legal & General Group Plc now owns 284,661 shares of the company’s stock worth $46,072,000 after acquiring an additional 27,945 shares during the period. 48.55% of the stock is owned by institutional investors.

Insider Transactions at BeiGene

In other news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO John Oyler sold 37,668 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the transaction, the chief executive officer now owns 12,332 shares in the company, valued at approximately $2,022,694.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,781 shares of company stock worth $10,222,381. Company insiders own 7.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BGNE shares. JPMorgan Chase & Co. raised their price target on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Guggenheim dropped their price objective on BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Sanford C. Bernstein dropped their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research note on Wednesday, March 27th. Finally, Bank of America dropped their price objective on BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research note on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $251.70.

BeiGene Trading Down 1.6 %

NASDAQ BGNE opened at $131.86 on Thursday. The stock’s 50-day simple moving average is $155.97 and its two-hundred day simple moving average is $169.12. BeiGene, Ltd. has a twelve month low of $131.28 and a twelve month high of $270.57. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $12.61 billion, a price-to-earnings ratio of -15.51 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, February 26th. The company reported ($3.53) EPS for the quarter, topping the consensus estimate of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The company’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($4.29) earnings per share. Research analysts forecast that BeiGene, Ltd. will post -8.87 EPS for the current fiscal year.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.